Caroline Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Yoo has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- David Y. Huang
UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA 90025, USA
2 shared publications - Elizabeth Evans
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, USA
2 shared publications - Yih-Ing Hser
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
2 shared publications - Andrew J. Saxon
Department of Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA, United States
1 shared publication - Yuhui Zhu
University of California, Los Angeles, California
1 shared publication
Latest Publications
Criminal justice outcomes over 5 years after randomization to buprenorphine‐naloxone or methadone treatment for opioid use disorder
Aims: To compare long‐term criminal justice outcomes among opioid‐dependent individuals randomized to receive buprenorphine or methadone. Design, setting and participants: A 5‐year follow‐up was conducted in 2011–14 of 303 opioid‐dependent participants entering three opioid treatment programs in California, USA in 2006–09 and randomized to receive either buprenorphine/naloxone or methadone. Intervention and comparator: Participants received buprenorphine/naloxone (BUP; n = 179) or methadone (MET; n = 124) for 24 weeks and then were tapered off their treatment over ≤ 8 weeks or referred for ongoing clinical treatment. Midway through the study, the randomization scheme was switched from 1 : 1 BUP : MET to 2 : 1 because of higher dropout in the BUP arm. Measurements: Study outcomes included arrests and self‐reported incarceration. Predictors included randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection in the 30 days prior to baseline and study site. Treatment status (buprenorphine, methadone, none) during follow‐up was included as a time‐varying covariate. Findings: There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow‐up. Among methadone‐randomized individuals, arrest was less likely with methadone treatment (0.50, 0.35–0.72) during follow‐up (relative to no treatment) and switching to buprenorphine had a lower likelihood of arrest than those receiving no treatment (0.39, 0.18–0.87). Among buprenorphine‐randomized individuals, arrest was less likely with receipt of buprenorphine (0.49, 0.33–0.75) during follow‐up and switching to methadone had a similar likelihood of arrest as methadone‐randomized individuals receiving no treatment. Likelihood of arrest was also negatively associated with older age (0.98, 0.96–1.00); it was positively associated with Hispanic ethnicity (1.63, 1.04–2.56) , cocaine use (2.00, 1.33–3.03), injection drug use (2.19, 1.26–3.83), and study site. Conclusions: In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment. Cocaine use, injection drug use, Hispanic ethnicity and younger age were associated with higher likelihood of arrest.
Criminal justice outcomes over 5 years after randomization to buprenorphine‐naloxone or methadone treatment for opioid use disorder
Aims: To compare long‐term criminal justice outcomes among opioid‐dependent individuals randomized to receive buprenorphine or methadone. Design, setting and participants: A 5‐year follow‐up was conducted in 2011–14 of 303 opioid‐dependent participants entering three opioid treatment programs in California, USA in 2006–09 and randomized to receive either buprenorphine/naloxone or methadone. Intervention and comparator: Participants received buprenorphine/naloxone (BUP; n = 179) or methadone (MET; n = 124) for 24 weeks and then were tapered off their treatment over ≤ 8 weeks or referred for ongoing clinical treatment. Midway through the study, the randomization scheme was switched from 1 : 1 BUP : MET to 2 : 1 because of higher dropout in the BUP arm. Measurements: Study outcomes included arrests and self‐reported incarceration. Predictors included randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection in the 30 days prior to baseline and study site. Treatment status (buprenorphine, methadone, none) during follow‐up was included as a time‐varying covariate. Findings: There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow‐up. Among methadone‐randomized individuals, arrest was less likely with methadone treatment (0.50, 0.35–0.72) during follow‐up (relative to no treatment) and switching to buprenorphine had a lower likelihood of arrest than those receiving no treatment (0.39, 0.18–0.87). Among buprenorphine‐randomized individuals, arrest was less likely with receipt of buprenorphine (0.49, 0.33–0.75) during follow‐up and switching to methadone had a similar likelihood of arrest as methadone‐randomized individuals receiving no treatment. Likelihood of arrest was also negatively associated with older age (0.98, 0.96–1.00); it was positively associated with Hispanic ethnicity (1.63, 1.04–2.56) , cocaine use (2.00, 1.33–3.03), injection drug use (2.19, 1.26–3.83), and study site. Conclusions: In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment. Cocaine use, injection drug use, Hispanic ethnicity and younger age were associated with higher likelihood of arrest.